Cytokinetics stops development of ALS drug
Cytokinetics Inc CYTK said on Friday it had stopped a late-study stage of its treatment for amyotrophic lateral sclerosis (ALS), as the drug was found to be ineffective.
Cytokinetics Inc CYTK said on Friday it had stopped a late-study stage of its treatment for amyotrophic lateral sclerosis (ALS), as the drug was found to be ineffective.